Brainjo Raises €2M to Advance VR Mental Healthcare
The Regensburg-based digital health company Brainjo has completed a €2 million seed funding round led by High-Tech Gründerfonds, with additional backing from strategic partners and private investors, including Andreas Weinhut and better ventures.
Healthcare systems continue to face pressure from limited therapy availability, extended waiting times, and restricted access to mental health services. Brainjo is developing solutions to address these challenges by using virtual reality as a prescribable extension of psychotherapy, with a focus on improving accessibility and patient engagement.
The company specialises in Digital Health Applications designed for prescription by medical professionals, including therapists and physicians, with costs eligible for reimbursement through health insurance. These applications are structured to complement rather than replace conventional psychotherapy. By incorporating immersive virtual reality environments, the solutions aim to provide individualised therapeutic support that can be accessed remotely from a patient’s home.
This model is intended to support continuity of care and address situations where traditional therapy alone may not fully meet patient needs. The use of digital tools is positioned as a means of extending treatment reach while maintaining integration with established clinical practices.
Brainjo operates with the objective of developing evidence-based therapeutic technologies that integrate into existing healthcare systems. Its approach centres on combining established treatment methods with digital innovation to expand the scope and scalability of mental health services.
The newly secured funding will be allocated to the company’s next stage of development, including conducting a clinical study and progressing through regulatory approval processes for its first virtual reality-based Digital Health Application. This initial product is focused on children diagnosed with attention-deficit/hyperactivity disorder and is being developed in collaboration with MEDICE – The Health Family.
The clinical and regulatory pathway is a key component of the company’s development strategy, as approval is required before the application can be introduced into standard healthcare provision. The process is expected to involve evaluation of clinical effectiveness, safety, and compliance with applicable healthcare regulations.
Market approval for the initial application is currently targeted for 2028. The timeline outlines the requirements for clinical validation and regulatory assessment in the digital health sector.
The participation of High-Tech Gründerfonds as lead investor, alongside contributions from strategic partners and individual investors, reflects continued interest in digital health innovation. The involvement of MEDICE – The Health Family as a development partner supports the integration of the application within established pharmaceutical and healthcare frameworks.
Brainjo’s development strategy remains focused on expanding access to mental healthcare by integrating digital tools that align with existing treatment models. The company continues to position its virtual reality-based applications as an adjunct to psychotherapy, aiming to support both patients and healthcare providers in addressing current limitations in mental health service delivery.
